Schizophrenia (SCZ) is a severe mental illness that is associated with an increased prevalence of age-related disability and morbidity compared to the general population. An accelerated aging process has therefore been hypothesized as a component of the SCZ disease trajectory. Here, we investigated differential aging using three DNA methylation (DNAm) clocks (i.e. Hannum, Horvath, Levine) in a multi-cohort SCZ whole blood sample consisting of 1,100 SCZ cases and 1,200 controls. It is known that all three DNAm clocks are highly predictive of chronological age and capture different features of biological aging.
Introduction
Schizophrenia (SCZ) is a severe psychiatric disorder with significant impact on the individual, their family, and society. A substantial proportion of people diagnosed with SCZ has chronic symptoms and disability across their lifespan [1] [2] [3] . SCZ is associated with an increased mortality [4] [5] [6] and a 15 year reduced life expectancy compared to the general population 7 . Despite elevated rates of suicide and other unnatural causes of death, most morbidity in SCZ is attributed to age-related diseases (e.g., cardiovascular and respiratory diseases, and diabetes mellitus 8, 9, 5 ). The increased prevalence of age-related disabilities and morbidities suggests that biological aging may be accelerated in SCZ 10, 11 . DNA methylation (DNAm) age predictors, or "epigenetic clocks", are biomarkers of ageing that generate a highly accurate estimate of chronological age, known as DNAm age [12] [13] [14] . The difference between (predicted) DNAm and chronological age (Δage) is associated with a wide-range of health and disease outcomes. For example, DNAm age acceleration in blood is associated with all-cause mortality [15] [16] [17] [18] , socioeconomic adversity and smoking 19 , metabolic outcomes, such as body mass index and obesity 20, 21 , and brain-related phenotypes, such as Parkinson's disease, posttraumatic stress disorder, insomnia, major depressive disorder, and bipolar disorder [22] [23] [24] 25, 26 .
While different aging biomarkers have been studied, there is no clear demonstration of altered aging in SCZ 11 . More specifically, DNAm age predictors have found limited to no evidence for altered epigenetic aging in either brain or blood [27] [28] [29] [30] [31] . These studies, however, (i) consisted of small sample sizes and thus limiting the ability to detect a biological signal, (ii) used a single epigenetic clock that may have not been most informative for aging studies of psychiatric disorders, and (iii) did not consider aging differences across the life-span of patients. As morbidities in the SCZ population differ between older and younger individuals, and females and males 5 , analyses of both age-and sex-specific effects is warranted and could identify differential aging patterns nevertheless.
To investigate DNAm aging in SCZ, we used three independent DNAm age estimators; the Hannum 13 , Horvath 12, 32 , and Levine clock 14 . Each clock is designed using different training features and capture distinct characteristics of aging 12, 32 : the Hannum age predictor was trained on whole blood adult samples, the Horvath predictor was trained across 30 tissues and cell types across developmental stages, and the Levine predictor combines DNAm from adult blood samples with clinical blood-based measures. As the Levine estimator is trained on chronological age and nine clinical markers, its output is referred to as DNAm PhenoAge or "phenotypic age". The Hannum estimator captures measures of cell extrinsic aging in blood, whereas the Horvath clock measures cell intrinsic aging as it was trained across multiple tissues and therefore is less dependent on cell type composition. All three clocks, in different but complementary ways, capture the pace of biological aging that is associated with age-related conditions and diseases, including allcause mortality 14, 32 .
Here, we used these clocks to investigate DNAm aging in SCZ using four European case-control cohorts. Analysis are performed across the full sample and stratified by age and sex. SCZ polygenic risk scores (PRS), age at onset, duration of illness, DNAm smoking scores, and blood cell type proportions were used to gain further insights into differential aging patterns. This study overall reports an in-depth investigation of the DNAm aging landscape in schizophrenia.
Material and Methods

Cohort and sample description
Details of samples included in this study can be found in the Supplementary Information. Briefly, unrelated individuals diagnosed with SCZ and ancestry-matched nonpsychiatric controls from four cohorts of European ancestry were included; the Netherlands (N=1,116), Scotland (N=847), Sweden (N=96), and the United Kingdom (N=675). Cases were selected on the basis of a clinical diagnosis of SCZ using the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV), Research Diagnostic Criteria (RDC), or the International Classification of Diseases 10 (ICD10). Controls were unaffected subjects without a history of any major psychiatric disorder. Whole blood DNAm data was available for a total of 2,707 samples (1,399 cases and 1,308 controls; (Table S1) .
Genome-wide DNA methylation profiling and data processing
To quantify DNA methylation, DNA was extracted from whole blood and bisulfite converted for hybridization to the Illumina Infinium Human Methylation Beadchip. Samples were assayed with either the 27K or 450K beadchip, which contain 27,578 and 485,512 probes that interrogate CpG sites across the genome, respectively. For each platform, data processing pipelines were implemented, which includes background correction, color channel and probe type correction, and normalization of the data, to minimize the effect of technical variation on the final beta values. Samples with more than 5% of probes detected at P > 0.05 were excluded from further analyses (n=13). Full details are described in the supplementary methods.
DNAm-based estimation of biological age
To compute blood-based DNAm age estimates, processed beta values were used as input to the Hannum 13 
Statistical analyses
To investigate epigenetic aging differences in SCZ, we first removed samples with discrepant phenotypic sex and predicted sex based on DNAm data (n=9), as well as samples with missing chronological age data (n=237), bipolar disorder diagnosis (n=26), and duplicate samples (n=126). For each epigenetic clock, we regressed Δage on technical principal components (PCs), using the first components that cumulatively explain >90% of variation in intensity values of control probes, and added the residuals to mean(Δage) to generate a measure in the same units as Δage that is adjusted for technical variation (Δageadjusted). We used the adjusted value for subsequent analyses and refer to it as Δage.
To avoid skewing of chronological age distribution between groups 33 , we removed any case older than the oldest control subject in each cohort (n = 5 for NLD, 16 for SCT, 4
for SWD, and 1 for UK). Chronological age was furthermore included as a covariate in all analyses. To minimize the effect of outlying samples, we excluded samples >3SD from mean Δage across cohorts (ranging from n=13 to 16 for the three clocks). These are samples for which DNAm age diverged substantially from chronological age, which are likely artifacts.
For each clock and each cohort, we implemented a multivariable regression model predicting Δage as a function of schizophrenia status, sex, and age. For the Dutch cohort, batch and array platform were also included as covariates, as this cohort consists of multiple datasets. For each clock, regression coefficients with corresponding standard errors for each of the four cohorts were then supplied to the rma() function of the metafor package 34 in R to fit a meta-analytic fixed-effect model with inverse-variance weights and obtain an overall effect size and test statistic. To quantify the significance of age-and sex-specific effects, we determined the contribution of interaction effects on top of the main disease effect. We first combined all cohorts to maintain necessary sample sizes across age and sex groups. Age groups were defined by grouping samples by decades with ages 18 and 19 included in the first decade (18-30, 31-40, etc.) . To quantify the gain in variance explained in Δage, models with the interaction term were compared to a baseline model without the interaction term.
For each analysis, statistical significance was determined using Bonferroni correction, i.e. P < 0.05 / number of tests.
SCZ polygenic risk quantification
Polygenic risk scores (PRS) were obtained from analyses of the SCZ GWAS conducted by Psychiatric Genomics Consortium (PGC) 35 . Using a leave one out approach, weights were generated in a training dataset based on all samples minus the target cohort in which the PRS were calculated. For each individual, weighted single nucleotide polymorphisms (SNPs) were summed to a genetic risk score that represents a quantitative and normally distributed measure of SNP-based SCZ genetic risk. To reduce between cohort-variation and maximize statistical power, we used a previously developed analytical strategy that uses principal component analysis (PCA) to concentrate disease risk across PRSs of ten GWAS p-value thresholds into the first principal component (PRS1) 36 (Supplementary Information). PRS1 explains 70.7% of the variance in risk scores and 19.9% of the variance in SCZ status; the remaining PCs had no explanatory value in disease status (mean R 2 = 0.0%), indicating that PRS1 captures the majority of SNP-based SCZ polygenic risk. PRS1 was generated for 1,933 individuals, 853 cases and 1080 controls, and modeled as both a quantitative and categorical variable to predict Δage.
Defining age at onset and illness duration
Age at onset is defined as the earliest reported age of psychotic symptoms or by the Operational Criteria Checklist (OPCRIT), depending on the cohort. This data is available for a subset of cases (N = 710) across the Dutch, Scottish, and UK cohorts. Illness duration is defined as the time between age at onset and blood collection. A more detailed description of each cohort's definition is available in the Supplementary Information.
DNA methylation-based smoking scores and blood cell type proportions
Smoking scores and blood cell type proportions were estimated from the data (see Supplementary Methods) and used as a proxy to further decompose differential aging effects.
Estimating the contribution of differential aging in schizophrenia
Using a multivariable logistic regression model for disease status, we fitted batch, cohort, DNAm smoking score, DNAm blood cell type proportions, and Δage as explanatory variables. We first performed a variable reduction step to select the most contributing variables to disease status by use of a regularized logistic regression using the glmnet() function in R ("glmnet" package, v2.13) 37 . Alpha was set to "1" (Lasso) and the lambda parameter estimated at the optimal value that minimizes the cross-validation prediction error rate using the cv.glmnet() function. For each selected variable, we then report the variance explained in SCZ status (glm, family = "binomial") for both the individual variable as well as adjusted for all other selected variables using the NagelkerkeR2() function in the "fmsb" package (v 0.6.3). The significance of each variable their contribution was computed by comparing the model with and without the variable of interest using the likelihood ratio test of the anova() function.
Availability of data and materials
The datasets used are available on the NCBI Gene Expression Omnibus (GEO) data repository, the European Genome-phenome Archive (EGA), or via the principal investigator of each cohort. See Table S2 and S3 for an overview and corresponding accession series numbers. See Table S4 for sample information, including DNAm age estimates. Figure 1 shows a schematic overview of the study design and analysis framework used to investigate DNAm aging in SCZ. After data preprocessing and quality control, 1,090 SCZ cases and 1,206 controls (2,296 subjects of 2,707 initial samples) were included in our analysis. The overall sample has a mean age of 40.3 years (SD=14.4) and consists of 34.5% women (Table S1 and Figure S1 ).
Results
[FIGURE 1 ABOUT HERE -SCHEMATIC OVERVIEW OF STUDY DESIGN]
Across cohorts, all three clocks produce a high correlation with chronological age (Pearson's r = 0.92-0.94; Figure 2A and S2). Using duplicates in the Dutch cohort, we assessed consistency between pairs of technical replicates, i.e. samples for which blood was collected at the same time but DNA processed at different times and DNAm data obtained on different arrays. Comparing Δage estimates between these pairs, we find a significant correlation for each clock ( Figure S3 ); Hannum (rho = 0.79, n = 10), Horvath (rho = 0.53, n=118), Levine (rho = 0.67, n=118). Δage directionality (i.e. age deceleration or acceleration) is concordant in 90%, 73%, and 86% of pairs for Hannum, Horvath, and Levine, respectively, highlighting that the obtained estimates of DNAm age are reproducible for all three clocks. Comparing Δage estimates between clocks using all samples, we find a moderate concordance (Pearson's r = 0.39-0.43; Figure S4 ), demonstrating that a significant proportion of the variation in Δage is clock-specific. This indicates that these estimators capture different features of biological aging and that investigating all three epigenetic clocks simultaneously may thus yield broader insights into differential aging.
[FIGURE 2 ABOUT HERE]
DNA methylation age is altered in an age-dependent manner
Across the full sample, SCZ cases are on average 1.53 years older in phenotypic Δage (Levine clock) compared to controls (P meta = 3.45E-08) ( Figure 2B ). The intrinsic cellular age (Horvath) predictor revealed an opposite pattern, with SCZ cases appearing 0.47 years younger compared to controls (P meta = 0.06). No differences were observed between cases and controls when applying the blood-based Hannum DNAm age predictor. No evidence of heterogeneity between the four cohorts was observed for any of the DNAm age analyses (P het > 0.05, Tables S5-S8).
Modeling the interaction effect between disease status and chronological age on
Δage reveals a differential rate of aging between cases and controls ( Figure 2C ). That is, the slope of Δage across chronological age is 0.05 and 0.06 years steeper in cases compared to controls for the Horvath (P meta =2.3E-03) and Levine clocks (P meta =7.1E-03), respectively ( Figure S5 and Table S6 ). As no significant effects were observed for the Hannum Δage, we decided to focus our downstream analysis on the phenotypic (Levine) age and intrinsic cellular (Horvath) age only. To further disentangle the relationship between Δage in SCZ conditional on chronological age, we estimated differential aging by 10 year intervals, with years 18 and 19 included in the first age group. We observe significant DNAm age deceleration in early adulthood (18-30 years) with cases estimated at -1.23 years younger (P meta =3.9E-03) in intrinsic cellular age with no significant difference at later ages ( Figure 3 ).
In phenotypic age, SCZ cases displayed significant DNAm age acceleration from 30 years and older, with the most pronounced age acceleration between 50-60 years (2.29 years, P meta =9.0E-03). We find no evidence of heterogeneity between cohorts ( Figure S6 and Table   S7 -8).
[ FIGURE 3 ABOUT HERE ]
Age-and sex-specific effects contribute independently to DNAm aging
To quantify the contribution of age-and also sex-specific effects, we estimated the gain in variance explained of Δage by adding the interaction terms of age and sex with disease status to a baseline model and assesed the gain in model performance ( Table 1 and S9). For intrinsic cellular aging, the baseline model explains 4.0% of the variance of Horvath
Δage. The variance explained increases significantly to 5.5% and 5.9% when a two-way interaction between status and (categorical) age and a three-way interaction between status, age, and sex is added, respectively. For phenotypic age, the baseline model explains 3.2% of the variance of Levine Δage. Similarly, the variance-explained of the Levine Δage signifcantly increases to 3.9% and 4.7%, respectively, with the interaction terms added to the model. For both measures of aging, inclusion of interaction terms presented a significantly better fit, especially with the three-way interaction model (i.e. disease status, categorical age and biological sex). We do observe a larger gain in model fit for the three-way interaction for phenotypic aging (P=0.01) than for intrinsic cellular aging (P=0. 24 ), suggesting that sexspecific effects may be less pronounced for Horvath Δage.
[ TABLE 1 ABOUT HERE ]
Estimating and mapping windows of differential aging in schizophrenia In order to refine the age-dependent aging effects and decompose its effect to more specific age windows, we implemented a sliding window approach across chronological age, both in the full sample and within each sex separately. Using 5-year bins and sliding steps of 1 year, we tested cases versus age-matched controls and constructed a more precise picture of differential aging across chronological age in SCZ (Figure 4 ). We mapped changes in Δage to specific ages with different patterns between men and women. For intrinsic cellular age, we observe a deceleration effect during early adulthood from 29 years and younger across all samples, with the shift in differential aging occurring earlier in women (<25) ( Figure 4B ). While we previously did not observe differences in intrinsic cellular aging across other categorical age groups (Figure 3 and S7) , the higher resolution, sliding window analysis reveals additional disease effects. For both men and women, we observe age deceleration in mid-forties and for women we also find age acceleration between 50-56 years ( Figure 4A-C) .
For phenotypic age, we mapped the age acceleration effect to 27 years and older across the whole sample with male / female differences ( Figure 4D-F) . In women, we observe age acceleration between 25-29 years and from 36 years and older ( Figure 4E ). In men, we see age acceleration between 27-39 and 49-59 years ( Figure 4F ). More details on each age window and corresponding effect sizes are shown in Table S10 . Thus far, our results show that DNAm aging, measured through the Horvath and Levine clock, is significantly different in SCZ and that this overall effect is characterized by age-specific effects with some distinctions between the sexes, particularly for Levine Δage.
[ FIGURE 4 ABOUT HERE ]
Age deceleration by multi-tissue Horvath clock is not present in brain
In order to examine whether the blood DNAm age findings are also observed in the brain, we investigated DNAm aging in frontal cortex postmortem brain samples of 221 SCZ cases and 278 controls. The multi-tissue Horvath clock accurately predicts DNAm age in brain as well (r=0.94, P < 2.2e-16). We however find no difference in DNAm aging between cases and controls (ß=-0.29, P=0.46) and no evidence of age-dependent aging either. More details are shown in the Supplementary Results (S2.1).
Phenotypic age acceleration is associated with SCZ polygenic risk in women
To further decipher the factors underlying the signal of differential aging in SCZ, we examined the possible role of SCZ polygenic risk (PRS1), age at onset, and illness duration ( Figure S8 ). We first focus on the phenotypic age acceleration in female cases of age 36 years and older, the age range which we identified as showing the most consistent and significant aging effect. We find stronger age acceleration in cases with both low and high SCZ genetic risk ( Table 2) . Cases in the highest PRS1 tertile are predicted to be 4.30 years older in phenotypic age compared to controls (P=1.3E-05), cases with median range PRS are 1.89 years older (P=4.5E-02), and cases in the lowest quartile are 2.89 years older (P=2.8E-03). By permutation of PRS1 groups, we find that the observed effect in female cases in the highest PRS1 group is unlikely to occur by chance (P=0.024). For the association between Levine Δage and PRS1 to be most pronounced in the low and high group, is even less likely to happen by chance (P=0.006). At maximum, this group of women carrying high SCZ genetic risk have on average 7.03 higher phenotypic Δage (95% CI: 3.87-10.18; P=1.7E-05) ( Figure 5A ). We do not observe such an association in women age < 36 years, men with age > 36 years, nor across the whole dataset ( Figure S9 ). For age at onset and illness duration, we did not find significant association with Δage across partitioned bins (after permutation, P > 0.05) ( Table 2 ). This is further confirmed when we integrated these two variables across PRS1 tertiles, demonstrating that the most pronounced differences in Δage are observed across PRS1 bins and not across the distribution of age at onset and illness duration ( Figure 5B -C).
[ TABLE 2 ABOUT HERE ]
We conducted a similar investigation on the observed intrinsic cellular age deceleration in all SCZ cases age 29 years and younger but found no significant associations between Horvath Δage and PRS1, age at onset, or illness duration (Table S11 and Figure S10 ). While we did observe the strongest Horvath age deceleration in the high PRS1 tertile (β=-1.58, P=3.0E-03), this was not significant after permutation analysis (P>0.05). We did not analyze other identified age windows of differential aging as these either had too few individuals with genetic or phenotypic information available or more modest disease effects limiting any further stratification.
[ FIGURE 5 ABOUT HERE ]
DNAm aging affects SCZ above and beyond smoking and blood cell types
People suffering from SCZ smoke more than the general population 38 (Figure 5A) and blood cell type composition changes across the lifespan 39 (Figure 5B ). To investigate the effect of these factors, we use DNAm-based smoking and cell type estimations (see Methods) as a proxy to evaluate their contribution to DNAm aging in SCZ. While DNAm clocks, by design, will encapsulate such effects, quantifying the contributions of each factor increases interpretability and helps understand the factors contributing to the differential aging findings. In women age 36 and older, the patient group in which we observed the most profound aging effects, a regularized logistic regression selected dataset/ethnicity, smoking, 5 cell types, and Levine Δage to explain a total of 23.6% of the variance in SCZ disease status (P=2.2E-08) (Table S12 ). Levine Δage explains 7.7% individually and 2.8% (P=3.3E-03) when adjusted for other selected variables ( Figure 6C ).
In individuals 29 years and younger, the group with the significant deceleration aging effects, the lasso regression selected batch/ethnicity, age, sex, smoking, 7 cell types, and
Horvath Δage, which together explain 49.8% of the variance in disease status (Table S12) . A large proportion of this effect is driven by smoking, which explains 28.8%. Horvath Δage explains 3.1% of the variance in SCZ individually and 0.6% adjusted for other select variables (P=0.14). A significant proportion of the Horvath Δage effect on disease status is reduced by adjusting for smoking. However, smoking has no association with Horvath Δage in controls (Pearson r=0.01, P=0.95) nor in cases (Pearson r=-0.08, P=0.28) ( Figure S12 ).
As smoking is confounded with SCZ disease status, it is difficult to distinguish these signals.
In relation to SCZ genetic risk, smoking and blood cell types demonstrate limited effects on the observed pattern of differential aging across PRS1 ( Figure S13 ).
Discussion
We performed one of the largest aging and epigenetic studies in schizophrenia to date using multiple epigenetic clocks based on whole blood DNA methylation data. We observe significant patterns of sex-specific and age-dependent DNAm aging in SCZ, a finding consistent across four European cohorts. The most significant differential aging pattern that we observe is in females ages 36 years and older in which we detect advanced phenotypic age acceleration, as measured by the Levine clock, explaining 7.7% of the variance in disease status. We also observe intrinsic cellular age deceleration in SCZ during early adulthood, as measured by the Horvath clock, explaining 3.1% of the variance in disease status. The phenotypic age acceleration in females diagnosed with SCZ is associated with a high burden of SCZ polygenic risk. This high SCZ risk group displays accelerated aging of an average of 7 years compared to age-matched female controls. Our findings suggests that specific and identifiable patient groups are at increased mortality risk as measured by the Levine clock.
The Levine estimator was constructed by predicting a surrogate measure of phenotypic age, which is a weighted average of 10 clinical markers, including chronological age, albumin, creatinine, glucose and C-reactive protein levels, alkaline phosphatase and various blood cell related measures 14 . By design, the Levine estimator is a composite biomarker that strongly predicts mortality, in particular that of cardiovascular-related phenotypes. A 1-year increase in Levine DNAm age is associated with a 9% increased risk of all-cause mortality and a 10% and 20% increase of cardiovascular disease and diabetes mortality risk, respectively 14, 40 . Our findings of multiple year increase in Levine DNAm age in SCZ could thus imply an increased mortality in these individuals that is linked to disease, a previously well-established epidemiological observation [4] [5] [6] . A recent study however found that DNAm age acceleration only predicts mortality in SCZ cases without pre-existing cancer using the Hannum clock 41 . They did not find such evidence using the Levine clock. The smaller sample size and predominantly male cohort may have reduced the predictive power of the study. Our findings warrant a more focused and larger study of DNAm aging in females in later adulthood, preferably stratified by SCZ genetic risk. Our results align well with the observation that people diagnosed with SCZ, particularly women, are reported to be at high mortality risk due to cardiovascular disease and diabetes 5, 42, 43 . Assuming that cardiovascular risk is modifiable in SCZ 44 , Levine DNAm age could serve as a potential biomarker to identify at-risk individuals and in this way help with disease management and improvement of life expectancy.
In contrast to age acceleration in Levine DNAm age, we observe age deceleration in intrinsic cellular age (i.e. the Horvath DNAm age), an effect that is most pronounced in cases age 29 and younger. Unlike the association in females, we did not observe clear patterns with genetic and phenotypic variables that could help deconstruct the signal. Horvath Δage furthermore showed strong age-specific effects but less clear sex-specific effects. We did not observe age deceleration in postmortem brain samples of the human cortex, indicating the the observe signal may be blood-specific. Horvath DNAm aging has been shown to associate with molecular processes of development and cell differentiation 12, 32 , including human (neuro)developmental phenotypes 45, 46 . Our findings may indicate that individuals diagnosed with SCZ in this age group show evidence of delayed or deficient development and that this is detectable in blood through the multi-tissue Horvath clock. This however remains speculative and future work is needed to further dissect how blood-based Horvath age deceleration is associated with SCZ.
While we did observe aging effects with the Horvath and Levine clock, we did not with the Hannum clock. The Hannum clock is less predictive of age acceleration effects on mortality risk than the Levine clock 14 , which could explain the lack of findings in our analyses. The Hannum estimator furthermore cannot be used on first generation 27K DNA methylation arrays which reduced the sample size of this study with 30% and may have impacted the statistical power of these specific analyses. This highlights the benefits of designing methods that are inclusive to all platforms, so all data, both old and new, can be leveraged.
Previous studies that investigated DNAm aging in SCZ did not observe significant differential aging [27] [28] [29] [30] [31] , highlighting that sample size and/or explicit modeling of age-and sexdependent effects are crucial factors when investigating aging in SCZ. Our findings also demonstrate that analyzing these clocks simultaneously can reveal new insights that may otherwise be missed. A systematic review of aging biomarkers found that less than a quarter of studies explored an interaction effect or statistically compared the regression slope between groups in SCZ 11 . Our findings support their recommendations to specifically examine age-specific effects in aging studies but also more general in epigenetic studies of SCZ, such as epigenome-wide association studies. Future work should also be extended to integrate nonlinear models to fully capture the complex relationship between DNAm aging and clinically relevant variables across the lifespan. These models will help validate and further refine the most relevant age intervals.
A limitation of the study is the cross-sectional design of the cohorts used. While we do find an association with SCZ polygenic risk, dissecting cause-and-effect relationships remains challenging. Large-scale longitudinal prospective cohorts with detailed clinical and genomic information are needed to further examine differential aging in SCZ and assess its clinical relevance above and beyond other known health risk factors and disease biomarkers, such as medication use. In addition, improvement of existing and/or development of new DNAm age biomarkers may help to better study differential aging in SCZ and related disorders with increased mortality. Combining blood-based DNAm age with that of other aging profiles, such as MRI-based brain age 47 , may further advance our understanding of aging and SCZ disease progression, including the increased mortality 48 .
Schizophrenia is a debilitating disorder that is associated with severe and oftentimes chronic disability. While health and life expectancy of the general population continues to improve, the mortality disparity between people suffering from schizophrenia and those unaffected continues to increase in the United States and the UK 8, 9, 42 . This highlights the importance of studies on improving the health and longevity of people with schizophrenia and other severe mental illnesses. Molecular biomarkers of aging, such as DNAm clocks, are emerging as candidate tools for screening and intervention. Our findings provide evidence of its potential in clinical care of SCZ. This study strengthens the need for future large-scale epidemiological studies of DNA methylation aging in SCZ, a population vulnerable to age-related diseases and excess mortality. Table S2 for more details on samples. DNAm age estimates were generated using three DNAm clocks, each designed to capture different features of aging (box 2). To investigate differences in aging between cases and controls, Δage Table 2 . Integration of Levine Δage with PRS, age of onset, and illness duration in women in later adulthod. Analyses were performed using women >36 years of age. Only cases with available information were included in the analyses. Each phenotype was analyzed as both a continuous variable and as a categorical variable using equal tertiles from low to high bins. Mean values in cases for each phenotype are presented along with the association with Δage (β) and corresponding 95% confidence intervals and p-values. PRS1 = polygenic risk score PC1 (see Supplementary Information) scaled to mean zero with standard deviation of 1, AOO = age of onset, DUR = illness duration. Asterisk* indicates that significance (P < 0.05) by permutation analyses.
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